Browsing by Author "Wang, L."

Now showing 1 - 3 of 3

Pmh13 - Examining Prevalence, Incidence and Mortality Rates Among Opioid-Dependent Patients in the U.s. Medicare Population
(Elsevier Science Inc, 2015) Li, L.; Shrestha, S.; Başer, Onur; Yuce H.; Li Wang; Yuce, H.; Wang, L.
OBJECTIVES: To examine incidence, prevalence and mortality rates among opioiddependent patients in the U.S. Medicare population. METHODS: A study was performed for the period from January 1, 2008 through December 31, 2012 to determinethe prevalence, incidence and mortality rates among opioid-dependent patients(International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes 304.0x and 304.7x) in the U.S. Medicare population. Patients who hadcontinuous fee-for-service Medicare health plan enrollment for the calendar yearand at least 2 years prior were selected for the study. Age- and gender-adjustedopioid dependence prevalence and incidence rates were calculated via direct standardization to the U.S. population age ?65 years in 2010 using gender-specific agegroups. RESULTS: The annual adjusted prevalence of opioid-dependent patientsincreased from 0.06% in 2008 to 0.35% in 2012. Incidence rates increased from 0.06%in 2008 to 0.10% in 2012. Prevalence rates were higher among women than men everyyear during the study period. Patients age 65-69 years had the highest prevalencerates during 2008 (0.09%), 2009 (0.16%), 2010 (0.22%) and 2011 (0.32%). However, in2012, patients who were age 70-74 years had the highest prevalence rates (0.43%).North American Natives had the highest prevalence of opioid dependence comparedto all other races. The highest incidence of opioid dependence was observed inNevada in 2008 (221.9 per 100,000 person-years) and 2012 (222.1 per 100,000 personyears). The 30-day and 1-year mortality rates decreased by 10.5% (3.8 to 3.4 per 1,000person-years) and 25.4% (17.3 to 12.9 per 1,000 person-years), respectively, from 2008to 2012. CONCLUSIONS: Opioid dependence incidence and prevalence decreasedfrom 2008 to 2012; however, opioid dependence-related mortality rates increased.
Pmh15 - Prevalence and Incidence Rates Among Alcohol-Dependent Patients in the Us Medicare Population
(Elsevier Science Inc, 2015) Li, L,; Shrestha, S.; Başer, Onur; Yuce H.; Li Wang; Yuce, H.; Wang, L.
OBJECTIVES: To examine incidence and prevalence rates among alcohol-dependentpatients in the U.S. Medicare population. METHODS: A prospective study was performed from 01JAN2008 through 31DEC2012 to determine the prevalence and incidence of patients diagnosed with alcohol dependence (International Classificationof Diseases, 9th Revision, Clinical Modification diagnosis code 303) in the U.S.Medicare population. Patients were required to have continuous enrollment in afee-for-service Medicare health plan during the calendar year and at least 2 yearsprior. The age- and gender-adjusted prevalence and incidence (overall and ageand gender-specific) rates of alcohol-dependent patients were calculated by directstandardization to the U.S. population age ?65 years in 2010. RESULTS: The annualadjusted overall prevalence rate increased from 0.30% in 2008 to 1.05% in 2012,whereas the annual overall incidence rate decreased from 0.30% in 2008 to 0.20%in 2012. Alcohol dependence prevalence and incidence rates were higher amongmen than women every year. Patients age 65-69 years had the highest prevalencerates during 2008 (0.43%) and 2009 (0.63%), whereas in 2010 (0.82%), 2011 (1.14%) and2012 (1.43%), patients age 70-74 years had the highest prevalence rates. Prevalencerates grew steadily among all age groups from 2008 to 2012. The highest alcoholdependence incidence rate was observed in the Virgin Islands (917.6 per 100,000person-years) in 2008, whereas in 2012, Wyoming (409.3 per 100,000 person-years)had the highest incidence rate. CONCLUSIONS: Increasing prevalence and decreas ing incidence of alcohol dependence was observed from 2008 to 2012. In addition,men were more likely to have alcohol dependence than women.
Pms37 - Health Care Cost Burden and Demographic Distribution of Patients Diagnosed With Psoriatic Arthritis in the Us Medicare Population
(Elsevier Science Inc, 2015) Li, L; Mao, X; Shrestha, S; Başer, Onur; Yuce H.; Li Wang; Yuce, H.; Wang, L.
OBJECTIVES: To investigate the health care cost burden and demographic distributionof patients diagnosed with psoriatic arthritis (PSA) in the Medicare fee-for-service(FFS) Dataset. METHODS: A retrospective database analysis was performed usingthe 100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012.Patients diagnosed with PSA were identified using International Classification ofDiseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 696.0, andthe index date was the date of the initial diagnosis. All patients were required to havecontinuous medical and pharmacy benefits 1-year pre- and post-index date. Healthcare costs and utilization during the baseline (1 year before the diagnosis date) andfollow-up (1 year after the diagnosis date) periods were calculated. RESULTS: Usingthe aforementioned criteria, 11,324 PSA patients were identified. The average ageat diagnosis was 74 years, 66.10% of patients were women and almost 92.36% werewhite. The majority of patients resided in the South U.S. region (39.01%). Diabetes(33.84%), chronic obstructive pulmonary disease (29.04%) and cerebrovascular disease(17.36%) were the main comorbidities observed during the baseline period. Duringthe follow-up period, 62.96% of patients had inpatient admissions, 47.29% had emergency room visits, 91.67% had outpatient office visits, 91.67% had outpatient visitsand 58.03% had pharmacy visits, costing, on average, $23,960, $237, $5,015, $5,252and $7,335, respectively. The average total cost of PSA patients was $36,548. The fivemost commonly prescribed medications for PSA were methotrexate sodium (4.54%),prednisone (3.37%), levothyroxine sodium (2.59%), hydrocodone bit/acetaminophen(2.43%) and simvastatin (2.11%). CONCLUSIONS: PSA patient demographic and healthcare cost information was obtained and the most commonly prescribed PSA medications were identified.